Karyopharm To Participate At The 2024 RBC Capital Markets Global Healthcare Conference
(MENAFN- PR Newswire) NEWTON, Mass., May 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), a commercial-stage Pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at
the 2024 RBC Capital Markets Global Healthcare conference in a fireside chat on Wednesday, May 15 at 9:30 a.m. ET.
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor
section of the Company's website,
, and will be available for replay following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI ) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including
Europe
and the
United Kingdom
(as NEXPOVIO®) and
China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
, and follow us on LinkedIn and on X at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
SOURCE Karyopharm Therapeutics Inc.
MENAFN08052024003732001241ID1108190642
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.